Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.

NCT01762202 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

80

Enrollment

OTHER

Sponsor class

Conditions

B-cell Lymphoid Leukemia
Young Patients

Interventions

DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Ofatumumab

Sponsor

Gruppo Italiano Malattie EMatologiche dell'Adulto